Cancer, 1L PI3Kα- mutated, HR+, HER2- metastatic breast cancer
RLAYRelay TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for RLY-2608 + fulvestrant + ribociclib (triplet) in Cancer, 1L PI3Kα- mutated, HR+, HER2- metastatic breast cancer. The expected timing is based on the latest available company guidance and may change.
ReDiscover trial. 2/22/24- Trial initiated. 11/06/25:- Trial ongoing. 12/12/25:- ReDiscover Ph1/2 triplet cohorts continue dose escalation to select regimen for potential frontline metastatic breast cancer trial. 02/26/26:- Triplet zovegalisib cohorts will report clinical data and frontline Ph3 design details during 2026. 05/05/26:- PR No update. 08/06/26:- PR No update.
Verification
Confirm timing and program details against the company announcement or filing.